Show Summary Details
Page of

Injectables 

Injectables
Chapter:
Injectables
Author(s):

Enda McVeigh

, John Guillebaud

, and Roy Homburg

DOI:
10.1093/med/9780199650682.003.0025
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 September 2021

Introduction

Mechanism of action and effectiveness

Indications

Advantages

Problems and disadvantages

Contraindications

Counselling and ongoing supervision

In the UK, the only injectable contraceptives licensed for long-term use are depot medroxyprogesterone acetate (DMPA) and, since 2013, the same progestogen given subcutaneously as Sayana Press®.

WHO data indicate that DMPA users have a reduced risk of cancer, with no overall increased risk of cancers of the breast, ovary, or cervix, and a 5-fold reduction in the risk of carcinoma of the endometrium (relative risk 0.2)....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.